OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/BRAF
Lung Cancer — Non-Small Cell (NSCLC)BRAF Clinical Trials
BRAF V600E mutations occur in 2–3% of NSCLC and are targetable with the FDA-approved dabrafenib plus trametinib combination. Non-V600 BRAF mutations (Class II and III) are less common and respond differently to BRAF/MEK inhibition. Clinical trials explore novel BRAF inhibitors, next-generation combinations, and strategies for non-V600E BRAF-altered NSCLC.
Top recruiting BRAF Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count. See all 29 trials matched to your profile →
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Summit Therapeutics
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NovoCure GmbH
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
Shouyao Holdings (Beijing) Co. LTD
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Sinocelltech Ltd.
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Cancer Research UK